Cargando…

Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria

The aim of this study is to evaluate the effect of the introduction of biosimilars in Bulgaria on the prices and utilization of biologic disease modifying antirheumatic drugs (bDMARD). It is a combined qualitative and quantitative analysis of time of entry of biosimilars on the national market and t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tachkov, Konstantin, Mitkova, Zornitsa, Boyadzieva, Vladimira, Petrova, Guenka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829887/ https://www.ncbi.nlm.nih.gov/pubmed/33466766 http://dx.doi.org/10.3390/ph14010064

Ejemplares similares

Biosimilar Insulins and Their Impact on Prices and Utilization of Insulins in Bulgaria
por: Tachkov, Konstantin, et al.
Publicado: (2021)

Analysis of Healthcare Expenditures in Bulgaria
por: Mitkova, Zornitsa, et al.
Publicado: (2022)

Utilization, Cost, and Affordability of Antihypertensive Therapy in Bulgaria
por: Mitkova, Zornitsa, et al.
Publicado: (2021)

Pharmacotherapeutic Patterns and Patients’ Access to Pharmacotherapy for Some Rare Diseases in Bulgaria – A Pilot Comparative Study
por: Kamusheva, Maria, et al.
Publicado: (2021)

Analysis of the Household and Health Care System Expenditures in Bulgaria
por: Mitkova, Zornitsa, et al.
Publicado: (2021)

Budget cap and pay-back model to control spending on medicines: A case study of Bulgaria
por: Mitkova, Zornitsa, et al.
Publicado: (2022)

New Epidemiological, Clinical and Economic Data for Patients With Acromegaly in Bulgaria
por: Kamusheva, Maria, et al.
Publicado: (2020)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
por: Prawjaeng, Juthamas, et al.
Publicado: (2023)

How Managed Entry Agreements Influence the Patients’ Affordability to Biological Medicines—Bulgarian Example
por: Mitkova, Zornitsa, et al.
Publicado: (2023)

Review of medicine utilization for Parkinson’s disease management: The Bulgarian perspective
por: Mitkova, Zornitsa, et al.
Publicado: (2021)

Аn affordability of statins therapy - comparative analysis between Ukraine and Bulgaria
por: Tkachova, Oksana, et al.
Publicado: (2019)

Life expectancy and survival analysis of patients with diabetes compared to the non diabetic population in Bulgaria
por: Tachkov, Konstantin, et al.
Publicado: (2020)

Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs)
por: Adami, Giovanni, et al.
Publicado: (2023)

bDMARDs retention rate in the biosimilar era: A real-life monocentric study
por: Becciolini, Andrea, et al.
Publicado: (2021)

Pilot Study on the Cost of Some Oncohematology Diseases in Bulgaria
por: Tachkov, Konstantin, et al.
Publicado: (2019)

Quality of Life and Cost Study of Rheumatoid Arthritis Therapy With Biological Medicines
por: Boyadzieva, Vladimira V., et al.
Publicado: (2018)

Treatment patterns, adherence to international guidelines, and financial mechanisms of the market access of advanced breast cancer therapy in Bulgaria
por: Karanyotova, Stephanie, et al.
Publicado: (2023)

Comparison of Cardiovascular Medicines Prices in Four European Countries
por: Mitkova, Zornitsa, et al.
Publicado: (2020)

Humanistic and economic aspects of haemophilia treatment in Bulgaria. Comparison between two therapeutic approaches: prophylactic vs. on-demand treatment
por: Petrova, Guenka, et al.
Publicado: (2014)

HBV and targeted synthetic (ts)DMARDs: what have we learned from bDMARDs and tsDMARDs?
por: Gremese, Elisa, et al.
Publicado: (2020)

A Systematic Review of Collective Evidences Investigating the Effect of Diabetes Monitoring Systems and Their Application in Health Care
por: Kamusheva, Maria, et al.
Publicado: (2021)

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1
por: Coates, Laura C, et al.
Publicado: (2017)

Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study
por: De La Fuente, Fanny, et al.
Publicado: (2022)

Effects of bDMARDs on quality of life in patients with psoriatic arthritis: meta-analysis
por: Lu, Yuqiong, et al.
Publicado: (2022)

Real World Experience of Disease Activity in Patients With Rheumatoid Arthritis and Response to Treatment With Varios Biologic DMARDs
por: Boyadzhieva, Vladimira, et al.
Publicado: (2018)

Risk of infection in postmenopausal women with rheumatoid arthritis and osteoporosis taking denosumab and bDMARDS
por: Mirzaei, Alireza, et al.
Publicado: (2021)

Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis
por: Van De Laar, Celine J, et al.
Publicado: (2020)

bDMARD Dose Reduction in Rheumatoid Arthritis: A Narrative Review with Systematic Literature Search
por: Verhoef, Lise M., et al.
Publicado: (2017)

Changes in the use patterns of bDMARDs in patients with rheumatic diseases over the past 13 years
por: Sánchez-Piedra, Carlos, et al.
Publicado: (2021)

Real-world comparative effectiveness of bDMARDs and JAK inhibitors in elderly patients with rheumatoid arthritis
por: Temmoku, Jumpei, et al.
Publicado: (2022)

Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries
por: Kawalec, Paweł, et al.
Publicado: (2017)

Molecular mechanisms of resistance to disease modifying antirheumatic drugs (DMARDs)
por: Jansen, G, et al.
Publicado: (2002)

Machine learning-based prediction model for responses of bDMARDs in patients with rheumatoid arthritis and ankylosing spondylitis
por: Lee, Seulkee, et al.
Publicado: (2021)

Clinical factors associated with discontinuation of ts/bDMARDs in rheumatic patients from the BIOBADASER III registry
por: Prior-Español, A., et al.
Publicado: (2021)

Stopping bDMARDs at the beginning of pregnancy is associated with disease flares and preterm delivery in women with rheumatoid arthritis
por: Gerardi, Maria Chiara, et al.
Publicado: (2022)

The impact of bDMARDs on postoperative complications in patients with rheumatoid arthritis: A systematic review and meta-analysis
por: Suto, Takahito, et al.
Publicado: (2023)

Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study
por: Jeong, Seogsong, et al.
Publicado: (2022)

Availability and reimbursement of biological products for severe asthma in Bulgaria
por: Milushewa, Petya, et al.
Publicado: (2020)

Chronic Hepatitis C-Related Cirrhosis Hospitalization Cost Analysis in Bulgaria
por: Dimitrova, Maria, et al.
Publicado: (2017)

ISO 9001 certification for hospitals in Bulgaria: does it help service?
por: Stoimenova, Assena, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_8e5738krj521ulpi2mm7bd3slp